Chimeric Antigen Receptor T-cell (CAR-T) therapy involves engineering a patient's T-cells to express receptors specific to cancer cells. Once infused back into the patient, these modified T-cells can aggressively target and destroy cancer cells. This personalized treatment has shown promising results, particularly in certain types of blood cancers like leukemia and lymphoma.
